The Influence Of Aqueous And Plasma Cytokines In Treatment Outcomes For Diabetic Macular Oedema
Funder
National Health and Medical Research Council
Funding Amount
$189,384.00
Summary
Diabetic macular oedema (DME) is the commonest cause of central visual loss in diabetics and has been linked to increased levels of vascular endothelial growth factor (VEGF) in the eye. DME is treated with anti-VEGF injections, but these need to be repeated, with some patients failing to respond. We plan to see if levels of VEGF and other inflammatory markers will predict treatment response, so those unlikely to respond can be spared futile treatment and receive alternative treatment earlier.